What is the 13F Pro Quality Score for COLL?

13F Pro ranks COLLEGIUM PHARMACEUTICAL, INC (COLL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View COLL's current score at https://13fpro.ai/research/COLL (free sign-up required for the full ranking).

Which hedge funds own the most COLL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of COLL include BlackRock,, JANUS HENDERSON GROUP PLC, Invesco Ltd.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/COLL as soon as new 13F filings post.

Where does 13F Pro source COLL data?

All COLLEGIUM PHARMACEUTICAL, INC fundamentals and ownership data come directly from SEC EDGAR. COLLEGIUM PHARMACEUTICAL, INC files with the SEC under CIK 1267565. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is COLL in?

COLLEGIUM PHARMACEUTICAL, INC (COLL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is COLL research updated on 13F Pro?

COLL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

COLLEGIUM PHARMACEUTICAL, INC(COLL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1267565 COLL stock profile & AI dashboard →

13F Pro Quality Score

60.8/100

Rank #831 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

77.9/100

Profitability

47.1/100

Balance Sheet

62.2/100

Earnings Quality

65.3/100

Free Cash Flow

88.1/100

Institutional Flow

42.2/100

Revenue Scale

44.5/100

Dilution Risk

24.9/100

COLL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for COLLEGIUM PHARMACEUTICAL, INC (COLL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores COLL at 60.8/100 on a 32-signal composite quality model, placing it at rank #831 of 2,879 stocks — the top half of the AI-ranked universe. COLL scores in the top quartile across free cash flow (88.1), revenue growth (77.9). Shareholder dilution risk is elevated at 24.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), COLLEGIUM PHARMACEUTICAL, INC reports quarterly revenue of $193.5M, net income of $14.5M, an operating margin of 16.0%. Top institutional holders of COLL by reported 13-F value include BlackRock,, JANUS HENDERSON GROUP PLC, Invesco Ltd., based on the most recent SEC filings. COLL trades on the Nasdaq exchange and files with the SEC under CIK 1267565. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COLL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for COLLEGIUM PHARMACEUTICAL, INC directly from SEC EDGAR. COLLEGIUM PHARMACEUTICAL, INC's 13F Pro composite quality score has ranged between 8 and 72 since 2021, currently 60.8 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$193.5M

Net Income

Q1 2026

$14.5M

Free Cash Flow

Q1 2026

$56.8M

Operating Margin

Q1 2026

16.0%

ROIC

Q1 2026

9.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+11.4% YoY

$631.4MFY 2024

FY21 $276.9MFY22 $463.9MFY23 $566.8MFY24 $631.4M

Net Income

+44.1% YoY

$69.2MFY 2024

FY21 $72.0MFY22 $-25.0MFY23 $48.0MFY24 $69.2M

Operating Income

+1.8% YoY

$169.9MFY 2024

FY21 $17.6MFY22 $33.3MFY23 $167.0MFY24 $169.9M

EPS (Diluted)

+44.2% YoY

$1.86FY 2024

FY21 $1.86FY22 $-0.74FY23 $1.29FY24 $1.86

Total Assets

+45.5% YoY

$1.66BFY 2024

FY21 $692.1MFY22 $1.17BFY23 $1.14BFY24 $1.66B

Total Debt

—FY 2024

FY21 —FY22 —FY23 —FY24 —

Op. Cash Flow

-25.4% YoY

$205.0MFY 2024

FY21 $103.6MFY22 $124.2MFY23 $274.7MFY24 $205.0M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$631.4M +11.4%	$566.8M +22.2%	$463.9M +67.6%	$276.9M -10.7%	$310.0M +4.5%	$296.7M
Net Income	$69.2M +44.1%	$48.0M +292.0%	$-25.0M -134.7%	$72.0M +169.1%	$26.8M +217.7%	$-22.7M
Operating Income	$169.9M +1.8%	$167.0M +401.1%	$33.3M +89.0%	$17.6M -68.7%	$56.2M +336.8%	$-23.7M
EPS (Diluted)	$1.86 +44.2%	$1.29 +274.3%	$-0.74 -139.8%	$1.86 +144.7%	$0.76 +211.8%	$-0.68
Total Assets	$1.66B +45.5%	$1.14B -2.6%	$1.17B +69.7%	$692.1M +7.5%	$643.8M +110.2%	$306.3M
Total Debt	—	—	—	—	—	$11.5M
Operating Cash Flow	$205.0M -25.4%	$274.7M +121.2%	$124.2M +20.0%	$103.6M +10.2%	$93.9M +238.1%	$27.8M

AI Insight: COLL Financial Trends

Revenue grew 34% year-over-year to $194M in Q1 2026, but operating income fell sharply to $31M from $61M in Q4 2025.

• Revenue increased from $178M in Q1 2025 to $194M in Q1 2026, representing 9% year-over-year growth.

• Operating cash flow strengthened from $55M in Q1 2025 to $57M in Q1 2026.

• Equity grew from $217M in Q2 2024 to $312M in Q1 2026, a 44% increase over eight quarters.

⚠ Operating income dropped 49% from $61M in Q4 2025 to $31M in Q1 2026, showing significant quarterly volatility.

⚠ Net income remains highly volatile, swinging from $32M in Q3 2025 to $17M in Q4 2025 to $14M in Q1 2026.

AI Insight: COLL Ratio Trends

Operating margin collapsed from 29.6% in Q4 2025 to 16.0% in Q1 2026, marking severe quarterly volatility despite strong Q3 2025 peak.

• Operating margin plunged 1,360bp from Q4 2025 (29.6%) to Q1 2026 (16.0%) following Q3 2025 peak of 29.7%.

• ROIC swung wildly from 37.0% in Q1 2025 to 90.4% in Q3 2025, then crashed to 39.6% in Q1 2026.

• Net profit margin dropped from 15.0% in Q3 2025 to 7.5% in Q1 2026 despite strong Q3 performance.

⚠ Extreme quarterly margin volatility suggests unstable underlying business fundamentals or lumpy revenue recognition patterns.

⚠ Q1 seasonality appears consistently weak with margins bottoming in both 2025 (12.2%) and 2026 (16.0%).

Get alerted when COLL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for COLLEGIUM PHARMACEUTICAL, INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of COLL

BlackRock, Inc.
$169.8M5,134,027 sh
JANUS HENDERSON GROUP PLC
$60.4M1,825,651 sh
Invesco Ltd.
$52.6M1,591,909 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$49.6M1,499,584 sh
RENAISSANCE TECHNOLOGIES LLC
$48.6M1,469,449 sh
STATE STREET CORP
$47.1M1,424,544 sh
EVENTIDE ASSET MANAGEMENT, LLC
$47.1M1,424,282 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$45.2M1,365,932 sh
VANGUARD CAPITAL MANAGEMENT LLC
$44.1M1,333,992 sh
PRINCIPAL FINANCIAL GROUP INC
$42.8M1,295,028 sh

Fund	Value	Shares
BlackRock, Inc.	$169.8M	5,134,027
JANUS HENDERSON GROUP PLC	$60.4M	1,825,651
Invesco Ltd.	$52.6M	1,591,909
FULLER & THALER ASSET MANAGEMENT, INC.	$49.6M	1,499,584
RENAISSANCE TECHNOLOGIES LLC	$48.6M	1,469,449
STATE STREET CORP	$47.1M	1,424,544
EVENTIDE ASSET MANAGEMENT, LLC	$47.1M	1,424,282
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$45.2M	1,365,932
VANGUARD CAPITAL MANAGEMENT LLC	$44.1M	1,333,992
PRINCIPAL FINANCIAL GROUP INC	$42.8M	1,295,028

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put COLL on your watchlist

Track score changes the day COLLEGIUM PHARMACEUTICAL, INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is COLL a good stock to buy?

13F Pro's AI-powered analysis of COLLEGIUM PHARMACEUTICAL, INC (COLL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for COLL are available on the COLL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own COLL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling COLL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of COLLEGIUM PHARMACEUTICAL, INC's investment landscape.